Little hope for Releaf Group creditors but investigations continue into asset sale by Steve Jones May 14, 2025May 14, 2025 Creditors are unlikely to see any return on the millions of dollars they are owed by […]
From tracking app to industry ally: OnTracka’s critical role in shifting the cannabis needle by Steve Jones May 13, 2025May 15, 2025
From visions of global leadership to an asset sale: where did it go wrong for Althea’s medical aspirations? by Steve Jones May 8, 2025May 8, 2025
Tasmanian Botanics to ‘breathe new life’ into Althea brand as it snaps up pharma assets for $1 million by Martin Lane and Steve Jones May 7, 2025May 8, 2025
SAS-B approvals hit all-time high in April as Tasmania spikes again by Steve Jones May 2, 2025May 2, 2025
Consistent supply a priority for ECS despite share price ‘frustration’ by Steve Jones April 30, 2025May 1, 2025
Cann Group expecting cash flow improvement but revenue falls 25% by Steve Jones April 30, 2025April 30, 2025
Althea considers exiting medicinal cannabis market amid sales collapse by Steve Jones April 30, 2025April 30, 2025
Prescribing guidance drawn up by ANZCCP to promote best practice by Steve Jones April 29, 2025April 29, 2025
Lack of funds hampers probe into failure of Melodiol Global Health by Steve Jones April 23, 2025April 23, 2025
